

Implications of coagulation factor VIII and IX pharmacological treatment of haemophilia

Haemophilia

17, 2-10

DOI: [10.1111/j.1365-2516.2010.02370.x](https://doi.org/10.1111/j.1365-2516.2010.02370.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Joint protection in haemophilia. <i>Haemophilia</i> , 2011, 17, 1-23.	1.0	107
2	Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1784-1790.	1.9	30
3	The factor VIII inhibitor assays can be standardized: results of a workshop. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2003-2008.	1.9	19
4	The Relevance of Factor VIII (FVIII) Pharmacokinetics to TDM and Hemophilia A Treatment: Is B Domainâ€“Deleted FVIII Equivalent to Full-Length FVIII?. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 110-117.	1.0	4
5	Collision Sports and Risk of Bleeding in Children With Hemophilia. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1480.	3.8	9
6	Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. <i>Blood</i> , 2012, 119, 612-618.	0.6	181
7	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. <i>Blood</i> , 2012, 120, 2405-2411.	0.6	160
8	Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1591-1599.	1.9	33
9	Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-FP), a glycoPEGylated recombinant factor IX. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2305-2312.	1.9	58
10	Octocog Alfa, Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®). <i>Drugs</i> , 2012, 72, 987-1007.	4.9	12
11	Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 969-977.	0.8	31
12	WFH: Closing the global gap â€“ achieving optimal care. <i>Haemophilia</i> , 2012, 18, 1-12.	1.0	86
13	Personalized prophylaxis. <i>Haemophilia</i> , 2012, 18, 131-135.	1.0	80
14	Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. <i>Haemophilia</i> , 2012, 18, 855-859.	1.0	44
15	Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 706-708.	1.9	21
16	The hope and reality of long-acting hemophilia products. <i>American Journal of Hematology</i> , 2012, 87, S33-9.	2.0	45
17	Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1119-1127.	1.9	173
18	Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1287-1297.	1.4	33

#	ARTICLE	IF	CITATIONS
19	Measurement of factor VIII pharmacokinetics in routine clinical practice. Journal of Thrombosis and Haemostasis, 2013, 11, 180-182.	1.9	49
20	Treatment of hemophilia B: focus on recombinant factor IX. Biologics: Targets and Therapy, 2013, 7, 33.	3.0	27
21	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood, 2013, 122, 1129-1136.	0.6	200
22	The hemophilias and their clinical management. Hematology American Society of Hematology Education Program, 2013, 2013, 261-267.	0.9	22
23	Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?. Haemophilia, 2013, 19, 882-886.	1.0	19
24	Evidence of clinically significant extravascular stores of factor IX. Journal of Thrombosis and Haemostasis, 2013, 11, 2176-2178.	1.9	52
25	Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia, 2013, 19, 481-486.	1.0	16
26	Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine [®]) and a recombinant factor IX (BeneFIX [®]) in patients with severe haemophilia B. Haemophilia, 2013, 19, 674-678.	1.0	27
27	Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia, 2013, 19, 409-414.	1.0	31
28	Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy. Haemophilia, 2013, 19, 808-813.	1.0	30
29	Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia, 2013, 19, 753-757.	1.0	38
30	Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2013, 102, 2380-2394.	1.6	7
31	Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica, 2013, 98, 1481-1486.	1.7	36
32	Climbing therapy under PK-tailored prophylaxis. Hamostaseologie, 2014, 34, S13-S16.	0.9	11
33	Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics: Targets and Therapy, 2014, 8, 115.	3.0	20
34	Management of hemophilia in Korea: the past, present, and future. Blood Research, 2014, 49, 144.	0.5	5
35	Contemporary Approaches to Hemophilia. , 2014, , .		0
39	Emerging Therapies for Hemophilia: A New Era of Care and the Role of the Interdisciplinary Team. Seminars in Thrombosis and Hemostasis, 2014, 40, 790-802.	1.5	5

#	ARTICLE	IF	CITATIONS
40	Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. <i>Haemophilia</i> , 2014, 20, 226-229.	1.0	31
41	Factor VIII therapy for hemophilia A: current and future issues. <i>Expert Review of Hematology</i> , 2014, 7, 373-385.	1.0	27
42	Recombinant factor VIII Fc fusion protein: extended interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1788-1800.	1.9	56
43	Considerations in individualizing prophylaxis in patients with haemophilia A. <i>Haemophilia</i> , 2014, 20, 607-615.	1.0	55
44	Prophylaxis in real life scenarios. <i>Haemophilia</i> , 2014, 20, 106-113.	1.0	22
45	Methods for individualising factor VIII dosing in prophylaxis. <i>European Journal of Haematology</i> , 2014, 93, 16-20.	1.1	31
46	Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. <i>Haemophilia</i> , 2014, 20, 398-406.	1.0	55
47	Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 932-940.	1.8	54
49	Current Issues in Hemophilia: Recognizing Clinical Heterogeneity, Replacement Therapy, and Outcome Assessment. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 816-818.	1.5	2
51	Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. <i>Haemophilia</i> , 2015, 21, 784-790.	1.0	37
52	Transition considerations for extended half-life factor products. <i>Haemophilia</i> , 2015, 21, 285-288.	1.0	17
53	The current status of prophylactic replacement therapy in children and adults with haemophilia. <i>British Journal of Haematology</i> , 2015, 169, 777-786.	1.2	52
54	Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics. <i>Journal of Blood Medicine</i> , 2015, 6, 185.	0.7	6
55	Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement. <i>Journal of Multidisciplinary Healthcare</i> , 2015, 8, 527.	1.1	16
56	The OPTI-CLOT trial. <i>Thrombosis and Haemostasis</i> , 2015, 114, 639-644.	1.8	22
57	Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. <i>British Journal of Haematology</i> , 2015, 169, 768-776.	1.2	51
58	Personalized approaches to the treatment of hemophilia A and B. <i>Personalized Medicine</i> , 2015, 12, 403-415.	0.8	2
59	Various regimens for prophylactic treatment of patients with haemophilia. <i>European Journal of Haematology</i> , 2015, 94, 11-16.	1.1	7

#	ARTICLE	IF	CITATIONS
60	Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 360-369.	1.9	74
61	The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from <sc>UKHCDO</sc>. <i>Haemophilia</i> , 2016, 22, 487-498.	1.0	97
62	Impact of being overweight on factor <sc>VIII</sc> dosing in children with haemophilia A. <i>Haemophilia</i> , 2016, 22, 361-367.	1.0	17
63	Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. <i>Haemophilia</i> , 2016, 22, e1-e10.	1.0	26
64	Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 468-478.	1.9	39
65	Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A. <i>BMC Hematology</i> , 2016, 16, 26.	2.6	5
66	New therapies for hemophilia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 650-656.	0.9	33
67	Musculo-skeletal manifestations of haemophilia. <i>Blood Reviews</i> , 2016, 30, 401-409.	2.8	38
68	Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. <i>Clinical Therapeutics</i> , 2016, 38, 936-944.	1.1	7
69	An innovative outcome-based care and procurement model of hemophilia management. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 337-345.	0.7	15
70	A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. <i>Blood</i> , 2016, 127, 1633-1641.	0.6	212
71	Medical comorbidities of patients with haemophilia: pain, obesity and hepatitis C. <i>Haemophilia</i> , 2016, 22, 47-53.	1.0	13
72	Dosing regimens, <sc>FVIII</sc> levels and estimated haemostatic protection with special focus on <sc>rFVIIIFc</sc>. <i>Haemophilia</i> , 2016, 22, 389-396.	1.0	33
73	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1105-1109.	1.9	54
74	2017 Clinical trials update: Innovations in hemophilia therapy. <i>American Journal of Hematology</i> , 2016, 91, 1252-1260.	2.0	82
75	Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2141-2147.	1.9	3
76	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. <i>Haematologica</i> , 2016, 101, 1159-1169.	1.7	39
78	Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products. <i>American Journal of Therapeutics</i> , 2016, 23, e1043-e1056.	0.5	16

#	ARTICLE	IF	CITATIONS
80	Primary prophylaxis in haemophilia care: Guideline update 2016. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 81-85.	0.6	29
82	Population pharmacokinetic characterization of <sc>BAY</sc> 81-8973, a full-length recombinant factor <sc>VIII</sc>: lessons learned - importance of including samples with factor <sc>VIII</sc> levels below the quantitation limit. <i>Haemophilia</i> , 2017, 23, 528-537.	1.0	35
83	What is the role for population pharmacokinetics in hemophilia?. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 125-136.	0.5	7
84	<sc>PK</sc>-guided personalized prophylaxis with Nuwiq [®] (human- ρ <sc>FVIII</sc>) in adults with severe haemophilia A. <i>Haemophilia</i> , 2017, 23, 697-704.	1.0	43
85	Exploring some intersections between pharmacokinetics, factor <sc>VIII</sc> measurement and human morphometrics - impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment. <i>Haemophilia</i> , 2017, 23, 488-490.	1.0	3
86	Hemophilia in Sports: A Case Report and Prophylactic Protocol. <i>Journal of Athletic Training</i> , 2017, 52, 65-70.	0.9	9
87	Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1045-1055.	1.6	31
89	PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. <i>Thrombosis Research</i> , 2017, 157, 58-63.	0.8	43
90	In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1737-1746.	1.9	12
91	Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices. <i>Haemophilia</i> , 2017, 23, 821-831.	1.0	11
92	Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2461-2465.	1.9	65
93	European retrospective study of real-life haemophilia treatment. <i>Haemophilia</i> , 2017, 23, 105-114.	1.0	61
94	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. <i>Pharmaceutics</i> , 2017, 9, 47.	2.0	17
95	Using pharmacokinetics to individualize hemophilia therapy. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 595-604.	0.9	39
96	Real life experiences of a <sc>PK</sc> dosing study - Challenges and lessons learned.. <i>Haemophilia</i> , 2018, 24, e145-e148.	1.0	2
97	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. <i>Blood Reviews</i> , 2018, 32, 265-271.	2.8	41
98	Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 143-151.	1.5	3
99	Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor <sc>VIII</sc>. <i>Haemophilia</i> , 2018, 24, 376-384.	1.0	16

#	ARTICLE	IF	CITATIONS
100	Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. <i>Thrombosis and Haemostasis</i> , 2018, 118, 514-525.	1.8	19
101	A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1123-1134.	1.6	65
102	Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. <i>Obesity Reviews</i> , 2018, 19, 1569-1584.	3.1	34
103	Evolving Complexity in Hemophilia Management. <i>Pediatric Clinics of North America</i> , 2018, 65, 407-425.	0.9	10
104	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 535-548.	1.0	50
105	Optimizing bleed prevention throughout the lifespan: Womb to Tomb. <i>Haemophilia</i> , 2018, 24, 76-86.	1.0	4
106	The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. <i>Thrombosis Research</i> , 2018, 170, 53-59.	0.8	4
107	Issues complicating precision dosing for factor VIII prophylaxis. <i>Transfusion and Apheresis Science</i> , 2018, 57, 472-479.	0.5	7
108	Optimization of prophylaxis for hemophilia A. <i>PLoS ONE</i> , 2018, 13, e0192783.	1.1	4
109	A novel, point-of-care, whole-blood assay utilizing dielectric spectroscopy is sensitive to coagulation factor replacement therapy in haemophilia A patients. <i>Haemophilia</i> , 2019, 25, 885-892.	1.0	11
110	Joint Bleeding Tendencies in Adult Patients With Hemophilia: It's Not All Pharmacokinetics. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986205.	0.7	12
111	Enhanced Factor IX Activity following Administration of AAV5-R338L α -Factor IX versus AAV5 WT Human Factor IX in NHPs. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 221-231.	1.8	19
112	Patient-centred care in haemophilia: Patient perspectives on visualization and participation in decision-making. <i>Haemophilia</i> , 2019, 25, 938-945.	1.0	11
113	Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 268-276.	1.0	12
114	The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. <i>Haemophilia</i> , 2019, 25, 676-684.	1.0	75
115	Risks and patient outcomes of surgical intervention for hemophilic arthropathy. <i>Expert Review of Hematology</i> , 2019, 12, 325-333.	1.0	11
116	Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate- and high-dose prophylaxis. <i>Haemophilia</i> , 2019, 25, 244-251.	1.0	16
117	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. <i>Blood Advances</i> , 2019, 3, 3241-3247.	2.5	85

#	ARTICLE	IF	CITATIONS
118	Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany. <i>Hamostaseologie</i> , 2019, 39, 355-359.	0.9	5
119	Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 88-98.	1.9	24
120	Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. <i>Thrombosis Research</i> , 2019, 174, 151-162.	0.8	27
121	Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. <i>Thrombosis Research</i> , 2019, 173, 79-84.	0.8	33
122	Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 702-712.	0.8	28
124	Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients. <i>Haematologica</i> , 2020, 105, 1443-1453.	1.7	18
125	Extended half-life recombinant products in haemophilia clinical practice â€“ Expectations, opportunities and challenges. <i>Thrombosis Research</i> , 2020, 196, 609-617.	0.8	18
126	Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A. <i>Thrombosis and Haemostasis</i> , 2020, 120, 277-288.	1.8	8
127	Clinical application of Web Accessible Population Pharmacokinetic Serviceâ€”Hemophilia (WAPPSâ€”Hemo): Patterns of blood sampling and patient characteristics among clinician users. <i>Haemophilia</i> , 2020, 26, 56-63.	1.0	7
128	Pharmacokinetics in routine haemophilia clinical practice: rationale and modalitiesâ€”a practical review. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096688.	1.1	12
129	Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1357-1370.	1.8	21
130	Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. <i>British Journal of Haematology</i> , 2020, 190, 684-695.	1.2	45
131	Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly. <i>Reports</i> , 2020, 3, 3.	0.2	0
132	Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. <i>Blood</i> , 2021, 137, 1818-1827.	0.6	43
133	A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1326-1336.	1.8	12
134	Exposureâ€”Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. <i>Clinical Pharmacokinetics</i> , 2021, 60, 931-941.	1.6	15
135	Tratamiento moderno de la hemofilia y el desarrollo de terapias innovadoras. <i>Investigacion Clinica</i> , 2021, 62, 73-95.	0.0	0
136	Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 889-900.	1.0	2

#	ARTICLE	IF	CITATIONS
137	Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. <i>Haemophilia</i> , 2021, 27, 626-633.	1.0	1
138	Haemophilia. <i>Nature Reviews Disease Primers</i> , 2021, 7, 45.	18.1	103
139	Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1896-1906.	1.9	12
140	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. <i>Haemophilia</i> , 2021, 27, 974-983.	1.0	3
141	Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. <i>Thrombosis Research</i> , 2021, 205, 99-105.	0.8	4
142	A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 232-244.	1.0	7
143	Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study. <i>European Journal of Pharmacology</i> , 2021, 891, 173764.	1.7	3
144	Musculoskeletal Manifestations of Hemophilia. , 2015, , 1-12.		2
145	Individualized approach to profilactic treatment in patients with severe hemophilia A. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2018, 5, 88-94.	0.1	2
146	Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?. <i>Blood Transfusion</i> , 2013, 11, 364-9.	0.3	25
147	Prophylaxis in haemophilia should be life-long. <i>Blood Transfusion</i> , 2012, 10, 165-8.	0.3	72
150	Extended Half-Life (EHL) Coagulation Factors: A New Era in the Management of Haemophilia Patients. <i>Turkish Journal of Haematology</i> , 2019, 36, 141-154.	0.2	23
151	Congenital hemophilia A with low activity of factor XII: a case report and literature review. <i>Italian Journal of Pediatrics</i> , 2021, 47, 204.	1.0	0
154	Into the future with novel emerging therapies for haemophilia. <i>The Journal of Haemophilia Practice</i> , 2015, 2, 24-25.	0.2	0
155	External qualification of the Web-Accessible Population Pharmacokinetic Service "Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12599.	1.0	0
156	Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2757-2768.	1.1	6
157	Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12686.	1.0	4
158	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. <i>HemaSphere</i> , 2022, 6, e694.	1.2	1

#	ARTICLE	IF	CITATIONS
159	Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A. <i>Thrombosis Research</i> , 2022, 213, 71-77.	0.8	5
160	How do we optimally utilize factor concentrates in persons with hemophilia?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 206-214.	0.9	4
161	Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?. <i>Haemophilia</i> , 2022, , .	1.0	2
162	Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience. <i>Haemophilia</i> , 2022, , .	1.0	1
163	Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A. <i>Haemophilia</i> , 2023, 29, 145-155.	1.0	3
164	Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	0
165	Update on the Treatment of Haemophilia A. <i>Advances in Clinical Medicine</i> , 2023, 13, 3973-3978.	0.0	0
166	Relationship between factor $VIII$ levels and bleeding for $rFVIII$ SingleChain in severe hemophilia A: A repeated time-to-event analysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 0, , .	1.3	1